CoChat

Ineffectiveness of Rosiglitazone Therapy in Nelson’s Syndrome

Open access
Munir, A., Song, F., Ince, P., Walters, S. J., Ross, R., Newell-Price, J. · 2007 · The Journal of Clinical Endocrinology & Metabolism
Cited by 42

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: Peroxisome proliferator-activated receptor (PPAR)-γ agonists have been proposed as therapy to lower plasma ACTH in Cushing’s disease. Cyclical secretion of ACTH may, however, explain some of the responses seen. Patients with Nelson’s syndrome have persistently high levels of ACTH and may be a better model for examining new therapies to elevated ACTH levels. Objective: The objective of the study was to assess whether high-dose rosiglitazone therapy reduces circulating ACTH levels in Nelson’s syndrome, a model of ACTH hypersecretion for which no established medical therapy exists. Design: The design was an open-label, prospective, nonrandomized study over 14 wk. Setting: The study was conducted at a university teaching hospital. Patients: Six patients with Nelson’s syndrome participated in the study. Methods: Patients were assessed at −2, 0, 4, 8, and 12 wk. Rosiglitazone 12 mg/d was administered between 0 and 8 wk. PPAR-γ immunoreactivity was assessed in pathological tissue. Outcome Measure: Plasma ACTH was measured before (0830 h) and 120 min after morning dosing with hydrocortisone (HC). Results: One female withdrew prior to commencing therapy for personal reasons. There was no evidence that ACTH levels changed over time (P = 0.864). The average ACTH level was 1187 ng/liter (95% confidence interval 928–1446) for patients before the HC dose and 432 ng/liter (95% confidence interval 172–692) after the HC dose. PPAR-γ immunoreactivity was positive in three ACTH-secreting tumors available. Conclusions: Rosiglitazone 12 mg/d did not change circulating ACTH over time, despite PPAR-γ receptor expression in the tumor tissue. However, this does not preclude the possibility that other patients may respond or that higher doses of rosiglitazone or more potent agonists might prove useful treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2006-2005

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 42

Metadata

Authors
Munir, A., Song, F., Ince, P., Walters, S. J., Ross, R., & Newell-Price, J.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2007-05-01
Volume
92
Issue
5
Pages
1758-1763
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2081625581
Cited by
42
References
2
FWCI
4.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.